Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Veen, J. Netelenbos (1990)
Growth hormone (replacement) therapy in adults: bone and calcium metabolism.Hormone research, 33 Suppl 4
J. Gallagher (1992)
Pathophysiology of osteoporosis.Seminars in nephrology, 12 2
R. Bouillon (1991)
Growth hormone and bone.Hormone research, 36 Suppl 1
G. Saggese, G. Baroncelli, S. Bertelloni, L. Cinquanta, Giovanna Nero (1993)
Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.The Journal of pediatrics, 122 1
S. Ezzat, S. Melmed, D. Endres, D. Eyre, F. Singer (1993)
Biochemical assessment of bone formation and resorption in acromegaly.The Journal of clinical endocrinology and metabolism, 76 6
C. Wüster (1993)
Growth hormone and bone metabolism.Acta endocrinologica, 128 Suppl 2
J. Dequeker, A. Burssens, R. Bouillon (1982)
Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis.Hormone research, 16 6
W. Harris, R. Heaney (1969)
Effect of Growth Hormone on Skeletal Mass in Adult DogsNature, 223
Jean-Marc Kaufman, P. Taelman, Alex Vermeulen, M. Vandeweghe (1992)
Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset.The Journal of clinical endocrinology and metabolism, 74 1
Bjarne, Lund, Peter Eskildsen, Birger, Anthony, W. Norman, Ole Helmer (1981)
Calcium and vitamin D metabolism in acromegaly.Acta endocrinologica, 96 4
E. Canalis, J. Pash, B. Gabbitas, S. Rydziel, S. Varghese (1993)
Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures.Endocrinology, 133 1
S. Kanzaki, Hosoda Kenji, T. Moriwake, Hiroyuki Tanaka, T. Kubo, M. Inoue, Johji Higuchi, T. Yamaji, Yoshiki Seino (1992)
Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy.The Journal of clinical endocrinology and metabolism, 75 4
E. Canalis, J. Lian (1988)
Effects of bone associated growth factors on DNA, collagen and osteocalcin synthesis in cultured fetal rat calvariae.Bone, 9 4
J. Johansen, S. Pedersen, J. Jørgensen, B. Riis, C. Christiansen, J. Christiansen, N. Skakkebaek (1990)
Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.The Journal of clinical endocrinology and metabolism, 70 4
D. Rudman (1985)
Growth Hormone, Body Composition, and AgingJournal of the American Geriatrics Society, 33
M. Slootweg, C. Hoogerbrugge, T. Poorter, S. Duursma, S. Buul-Offers (1990)
The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: autocrine/paracrine growth effect of IGFs?The Journal of endocrinology, 125 2
J. Christiansen, Jol Jørgensen, S. Pedersen, Jørn Müller, Jens Jørgensen, Jens Møller, L. Heickendorf, N. Skakkebaek (1991)
GH-replacement therapy in adults.Hormone research, 36 Suppl 1
O. Isaksson, A. Lindahl, A. Nilsson, J. Isgaard (1987)
Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth.Endocrine reviews, 8 4
Abstract GH has considerable importance in the normal development and growth of bone. An additional role in the maintenance of the adult skeleton is suggested by the alterations in bone mineral density observed in states of deficient or excess GH secretion and in the bone formation response to GH replacement in GHD patients. Deficiency in the secretion of GH is also observed, with increasing and striking frequency after middle-age despite the lack of any defined pituitary disease or injury. Although a causal relationship between hyposomatotropism and osteopenia in normal elderly patients is hypothetical, intriguing therapeutic questions are raised. Preliminary trials of hGH in osteoporosis have not resulted in increases in BMD, but such studies suffer from methodological limitations, chief of which is the failure to account for the GH/IGF-I status of their subjects. Osteopenic patients with the lowest IGF-I levels may need to be assessed independently. The utility of hGH may be in preventing the senile component of osteoporosis, which appears to result mainly from defective bone formation. Such studies will require appropriate patient selection, longer treatment periods, and more sensitive measures of bone density. Combination and/or coherence therapy with other agents, particularly those that attenuate bone resorption, may also prove useful. This content is only available as a PDF. Copyright © 1994 by The Endocrine Society
Journal of Clinical Endocrinology and Metabolism – Oxford University Press
Published: Sep 1, 1994
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.